Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.

In the majority of patients responding to TKI therapy, chronic myeloid leukemia (CML) is now managed like a chronic disease. However, it poses significant challenges to the clinicians in terms of selection of alternate TKI therapy in patients with inadequate initial response to initial TKI therapy. Informing clinicians about the recent FDA approvals would assist in the incorporation of new treatment options into their routine clinical practice to improve patient outcomes.

It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.

To help patients have the best outcomes possible, clinicians need education on selection of therapy (high-intensity, low-intensity, or targeted) and on how best to manage toxicities and provide supportive care.